Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphoid leukemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    380 result(s) found for: Lymphoid leukemia. Displaying page 4 of 19.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-003902-28 Sponsor Protocol Number: CAMN107A2409 Start Date*: 2013-03-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multi-center nilotinib roll-over protocol for patients who have completed a previous Novartis-sponsored nilotinib study and are judged by the investigator to benefit from continued ...
    Medical condition: Patients who are on nilotinib treatment in a Novartis-sponsored, Oncology Global Development & Global Medical Affairs study and are benefiting from the treatment as judged by the investigator. All ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    20.0 100000004864 10001690 ALL LLT
    21.0 100000004864 10009700 CML LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed) ES (Ongoing) HU (Completed) NL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003235-20 Sponsor Protocol Number: NOPHO-ALL-2008 Start Date*: 2008-10-10
    Sponsor Name:Rigshospitalet
    Full Title: NOPHO-ALL-2008 Treatment Protocol for Children (1.0 - 17.9 years of age) with Acute Lymphoblastic Leukemia
    Medical condition: Acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) SE (Completed) FI (Completed) LT (Prematurely Ended) IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012957-39 Sponsor Protocol Number: CLL2P Start Date*: 2010-12-23
    Sponsor Name:University of Cologne
    Full Title: A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia
    Medical condition: Patients (age 18 or older) with relapsed or refractory chronic lymphocytic leukemia requiring treatment
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008976 Chronic lymphocytic leukemia LLT
    12.1 10008977 Chronic lymphocytic leukemia recurrent LLT
    12.1 10008978 Chronic lymphocytic leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003180-31 Sponsor Protocol Number: MC-ASP.5/ALL Start Date*: 2008-07-29
    Sponsor Name:medac GmbH
    Full Title: Comparative efficacy and safety of two asparaginase preparations in children with previously untreated acute lymphoblastic leukaemia
    Medical condition: Acute lymphoblastic leukaemia (ALL) is a clonal disease resulting from genetic mutations and transformation of a single early progenitor lymphoid cell. Uncontrolled expansion of leukaemic blasts in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-015989-62 Sponsor Protocol Number: MT103-206 Start Date*: 2010-08-05
    Sponsor Name:Amgen Research (Munich) GmbH
    Full Title: An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Ac...
    Medical condition: Patients with Relapsed/Refractory B-Precursor acute lymphoblastic leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003303-30 Sponsor Protocol Number: 2014-003303-30 Start Date*: 2015-05-22
    Sponsor Name:Dutch Childhood Oncology Group
    Full Title: TropicALL study; Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a randomized controlled trial
    Medical condition: Acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000424-86 Sponsor Protocol Number: Start Date*: 2008-11-25
    Sponsor Name:Erasmus MC
    Full Title: Development and introduction of a pediatric liquid formulation of 6-mercaptopurine for treatment of leukemia
    Medical condition: Acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001507-39 Sponsor Protocol Number: GEN416 Start Date*: 2009-01-16
    Sponsor Name:GlaxoSmithKline
    Full Title: A single-arm, international, multi-center trial investigating the efficacy and safety of ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia who pr...
    Medical condition: B-cell Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) SE (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004090-26 Sponsor Protocol Number: 6MP/6TG-01 Start Date*: 2008-03-25
    Sponsor Name:Rigshospitalet
    Full Title: IMPROVING THIOPURINE/METHOTREXATE MAINTENANCE THERAPY OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA
    Medical condition: Acute Lymphoblastic Leucemia in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-013271-22 Sponsor Protocol Number: GIMEMA LAL1408 Start Date*: 2009-11-09
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL`ADULTO
    Full Title: Front-line treatment of Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL) with two tyrosine kinase inhibitors (TKI) (Imatinib and Nilotinib). A phase II exploratory multicentr...
    Medical condition: Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004877-42 Sponsor Protocol Number: PETHEMA-BLIN-01 Start Date*: 2018-04-25
    Sponsor Name:FUNDACIÓN PETHEMA
    Full Title: A phase II, open-label study to evaluate the effect of blinatumomab administered during consolidation to reduce the level of minimal residual disease (MRD) assessed through flow cytometry in adult ...
    Medical condition: Acute lymphoblastic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001738-17 Sponsor Protocol Number: GIMEMALAL0904 Start Date*: 2004-11-08
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: Evaluation of the intensification of post-remissional therapy in the treatment of high-risks adult Acute Lymphoblastic Leukemia and monitoring of the minimal residual disease
    Medical condition: Patients with T- and B-ALL; Age >14 and <61 years
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000846 Acute lymphocytic leukaemia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003820-30 Sponsor Protocol Number: HYD-HD85/45-CLL-02 Start Date*: 2016-02-22
    Sponsor Name:HYD Pharma Zrt.
    Full Title: A MULTICENTER, SINGLE ARM, OPEN LABEL, EXPLORATORY PROSPECTIVE PHASE II STUDY TO EXPLORE THE EFFICACY, SAFETY AND TOLERABILITY OF DEUTERIUM DEPLETED WATER IN PREVIOUSLY UNTREATED PATIENTS WITH ASYM...
    Medical condition: Previously untreated patients with asymptomatic chronic lymphocytic leukemia but who are at high risk of progression.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10060576 Chronic lymphoid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002972-29 Sponsor Protocol Number: CART19-BE-01 Start Date*: 2017-05-16
    Sponsor Name:IDIBAPS
    Full Title: Pilot study on the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (...
    Medical condition: Patients with leukemia or lymphoma refractory to therapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008957 Chronic lymphatic leukemia LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029473 Nodular (follicular) lymphoma LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000843 Acute lymphatic leukemia LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000297-38 Sponsor Protocol Number: CL1-68587-003 Start Date*: 2016-06-22
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S)
    Full Title: Long-term follow-up study of patients who have previously been exposed to UCART19 / ALLO-501 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)
    Medical condition: Advanced lymphoid malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060390 Leukaemia lymphoblastic acute LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000296-24 Sponsor Protocol Number: CL1-68587-002 Start Date*: 2017-10-20
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S)
    Full Title: Phase I, open label, dose-escalation study to evaluate the safety, expansion and persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen recepto...
    Medical condition: Patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10060390 Leukaemia lymphoblastic acute LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004551-20 Sponsor Protocol Number: GS-US-312-0118 Start Date*: 2015-07-02
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Un...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) PT (Prematurely Ended) HU (Completed) ES (Completed) BE (Prematurely Ended) BG (Prematurely Ended) HR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000600-15 Sponsor Protocol Number: PCI-32765CLL3001 Start Date*: 2012-09-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or...
    Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) ES (Completed) PT (Completed) GB (Completed) DE (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000074-19 Sponsor Protocol Number: GCP#03.01.020 Start Date*: 2014-10-24
    Sponsor Name:Gamida Cell Ltd
    Full Title: Full title of the trial: Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescents and Adult Patients with Hematologic...
    Medical condition: High risk haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    17.0 100000004864 10025316 Lymphoma NOS LLT
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    17.0 100000004864 10009015 Chronic myeloid leukemia LLT
    17.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-001101-52 Sponsor Protocol Number: CART19-BE-03Ped Start Date*: 2022-11-07
    Sponsor Name:Fundació Privada per a la Recerca i la Docència Sant Joan de Déu
    Full Title: Phase 2 study of the infusion of autologous, differentiated, peripheral blood T-cells expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3...
    Medical condition: CD19+ acute lymphoid leukemia resistant or refractory to treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10060555 Acute lymphoid leukemia LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 00:26:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA